Skip to main content

Investor Relations

Corporate Profile

3DBio, headquartered in New York City (Long Island City, Queens), is a clinical-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and materials technologies to deliver safe, functional and personalized living tissues and organs, engineered on-demand for patients. 3DBio’s pioneering approach develops living tissue implants with structural and functional integrity with a four-part technology platform, including: novel and proprietary 3D-bioprinter (GMPrint™), bio-ink (ColVivo™), specialized cell culture system, and implantable protective shell (Overshell Technology). Today, 3DBio is breaking new ground with a clinical trial underway to treat Microtia, three additional programs nearing the clinic, and multiple life-changing treatment approaches in development. 3DBio is committed to providing healthcare professionals with safe and functional implant solutions delivering optimal patient outcomes.

Latest Updates

3D Bio Therapeutics EarNews
June 2, 2022

Doctors Transplant Ear of Human Cells, Made by 3-D Printer

3DBio Therapeutics, a biotech company in Queens, said it had for the first time used 3-D printing to make a body part with a patent’s own cells. View Full New…
3D Bio Therapeutics EarPress Releases
June 2, 2022

3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

- AuriNovo™ an investigational, 3D-bioprinted implant was created using a proprietary process leveraging the patient’s own tissue to generate an implantable ear - - Phase 1/2a clinical trial enrolling patients…
Pod cast IconNews
October 23, 2021

3DBio on Finding Genius Podcast

Finding Genius Podcast (Oct. 23, 2021 Episode) 3DBio: Printing Living Human Tissues for Therapeutic Applications   Press play to learn: The most common problems with synthetic implants How 3D bioprinting…